Drug Profile
Research programme: RNA virus vaccines - Sementis/University of South Australia
Alternative Names: Chikungunya vaccine - Sementis; SCV 301C; Zika virus vaccine - SementisLatest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator Sementis; University of South Australia
- Class Synthetic vaccines; Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chikungunya virus infections; Zika virus infection
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Australia (SC)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Chikungunya-virus-infections(Prevention) in Australia (SC)
- 05 Nov 2018 Sementis in-licenses ImplaVax® technology to develop RNA virus vaccines implant for Chikungunya virus infections and Zika virus infection